BioLine RX Ltd ADR buy tamam
Start price
06.08.17
/
50%
€225.27
Target price
03.06.19
€608.85
Performance (%)
-67.57%
End price
03.06.19
€73.06
Summary
This prediction ended on 03.06.19 with a price of €73.06. Massive losses of -67.57% were the result for the BUY prediction by tamam. tamam has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| BioLine RX Ltd ADR | -6.299% | -6.299% | -38.660% | -76.389% |
| iShares Core DAX® | 0.961% | -2.210% | 12.839% | 17.154% |
| iShares Nasdaq 100 | 2.626% | -1.918% | 38.498% | 45.463% |
| iShares Nikkei 225® | 0.217% | -7.216% | 19.425% | 5.076% |
| iShares S&P 500 | 1.540% | -1.858% | 27.801% | 42.583% |
Comments by tamam for this prediction
In the thread BioLine RX Ltd ADR diskutieren
BioLineRx in partnership with Novartis and collaboration with Roche
BioLineRx might be one of the best biotech values in the stock market, as it has a promising
pipeline, a cash-rich balance sheet and a low burn rate.
This stock dropped many weeks ago when the company announced a secondary offering, but it has since built a strong base and could be poised to rebound.
The pipeline is promising with its lead candidate BL-8040 being a potential blockbuster with multiple indications.
A leading biotech fund and Novartis have taken a major stake in this company and analyst price targets of $3 to $4 per share, suggests significant upside.
BioLineRx (NASDAQ:BLRX) initiated with Outperform rating and $3 (186% upside) price target by Oppenheimer.
(Vom Mitglied beendet)